New Antibodies Released from DBS

Diagnostic BioSystems is very excited to announce the release of three new primary antibodies specially effective in Bladder Cancer Applications:

Uroplakin II Antibody

Uroplakin II (UPII) is a newly described sensitive marker for urothelial carcinoma (UC).

• Uroplakin II (UPII) and p40 antibodies are high specificity in urothelial carcionoma.
• Uroplakin II is a more sensitive immunohistochemical marker that uroplakin III in urothelial carcinoma.
• Its advantages in the differential diagnosis of urothelial carcinoma and in the detection of tumors of unknown origin.

View product datasheet

Ordering information:

Uroplakin III Antibody

Uroplakin III is specific for tumors of urothelial origin and, when used in combination with other markers, can aid in the diagnosis of primary and metastatic tumors.

• Characterize urothelial lesions and differentiate from prostatic penile, vulvar or renal lesions.
• Applicable for forensic urine identification by immunohistochemisty.
• IHC positive stain in Ovarian Brenner tumor.

View product datasheet

Ordering information:

Uroplakin II & III Cocktail Antibody

Uroplakin II/III cocktail is specific for tumors of urothelial origin and, when used in combination with other markers, can aid in the diagnosis of primary and metastatic tumors.

• UPII and UPIII are sensitive and highly specific markers for unothelial carcinoma.
• UPII and UPIII have been found to be highly sepcific when evaluated in various normal and neoplastic tissues, including brest, lung, colon, prostate, kidney, ovarian, liver andpancreatic cancers.
• A sensitive marker for urothelial carcinoma and valuable in the discrimination of bladder cancer from renal and prostate carcinomas.

View product datasheet

Ordering information: